WO2013054525A1 - グルタチオン含有健康飲料 - Google Patents
グルタチオン含有健康飲料 Download PDFInfo
- Publication number
- WO2013054525A1 WO2013054525A1 PCT/JP2012/006525 JP2012006525W WO2013054525A1 WO 2013054525 A1 WO2013054525 A1 WO 2013054525A1 JP 2012006525 W JP2012006525 W JP 2012006525W WO 2013054525 A1 WO2013054525 A1 WO 2013054525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutathione
- vitamin
- beverage
- expression
- chondroitin
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 168
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 81
- 229960003180 glutathione Drugs 0.000 title claims abstract description 80
- 230000036541 health Effects 0.000 title claims abstract description 45
- 230000014509 gene expression Effects 0.000 claims abstract description 57
- 210000004369 blood Anatomy 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 42
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims abstract description 41
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 37
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 36
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 35
- 229920002567 Chondroitin Polymers 0.000 claims abstract description 31
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims abstract description 31
- 229940088594 vitamin Drugs 0.000 claims abstract description 29
- 229930003231 vitamin Natural products 0.000 claims abstract description 29
- 235000013343 vitamin Nutrition 0.000 claims abstract description 29
- 239000011782 vitamin Substances 0.000 claims abstract description 29
- 230000035882 stress Effects 0.000 claims abstract description 21
- 108050002069 Olfactory receptors Proteins 0.000 claims abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 41
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 claims description 40
- 229950009829 prasterone sulfate Drugs 0.000 claims description 40
- 102000008186 Collagen Human genes 0.000 claims description 33
- 108010035532 Collagen Proteins 0.000 claims description 33
- 229920001436 collagen Polymers 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 30
- 102000011931 Nucleoproteins Human genes 0.000 claims description 27
- 108010061100 Nucleoproteins Proteins 0.000 claims description 27
- 239000011701 zinc Substances 0.000 claims description 26
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 25
- 229910052725 zinc Inorganic materials 0.000 claims description 25
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 20
- 229930003268 Vitamin C Natural products 0.000 claims description 20
- 239000011718 vitamin C Substances 0.000 claims description 20
- 235000019154 vitamin C Nutrition 0.000 claims description 20
- 230000032683 aging Effects 0.000 claims description 18
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 17
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 17
- 229940041514 candida albicans extract Drugs 0.000 claims description 16
- 239000012138 yeast extract Substances 0.000 claims description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 12
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 9
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 101150031682 TNFRSF10C gene Proteins 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 abstract description 104
- 230000000694 effects Effects 0.000 abstract description 51
- 230000006872 improvement Effects 0.000 abstract description 42
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- 210000000467 autonomic pathway Anatomy 0.000 abstract description 13
- 102000012547 Olfactory receptors Human genes 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 11
- 230000009759 skin aging Effects 0.000 abstract description 8
- 230000003716 rejuvenation Effects 0.000 abstract description 6
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 38
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 38
- 230000037406 food intake Effects 0.000 description 37
- 238000000034 method Methods 0.000 description 37
- 229920002477 rna polymer Polymers 0.000 description 30
- 239000000523 sample Substances 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 23
- 230000007423 decrease Effects 0.000 description 23
- 230000003247 decreasing effect Effects 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- 238000008214 LDL Cholesterol Methods 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 229940107161 cholesterol Drugs 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- -1 hyaluronic acid Chemical class 0.000 description 8
- 230000036651 mood Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 208000027534 Emotional disease Diseases 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000037394 skin elasticity Effects 0.000 description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000002567 autonomic effect Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000004879 molecular function Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 206010020400 Hostility Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000004108 pentose phosphate pathway Effects 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000697 sensory organ Anatomy 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000002459 polyene antibiotic agent Substances 0.000 description 3
- 229960002847 prasterone Drugs 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 241000235646 Cyberlindnera jadinii Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 101000594780 Homo sapiens Olfactory receptor 14I1 Proteins 0.000 description 2
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 2
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LVFFZQQWIZURIO-UHFFFAOYSA-N 2-phenylbutanedioic acid Chemical compound OC(=O)CC(C(O)=O)C1=CC=CC=C1 LVFFZQQWIZURIO-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000199912 Crypthecodinium cohnii Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150060989 DOA1 gene Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241001465321 Eremothecium Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100033924 GS homeobox 2 Human genes 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001068302 Homo sapiens GS homeobox 2 Proteins 0.000 description 1
- 101000986598 Homo sapiens Mas-related G-protein coupled receptor member X3 Proteins 0.000 description 1
- 101000611355 Homo sapiens Olfactory receptor 1F1 Proteins 0.000 description 1
- 101001086423 Homo sapiens Olfactory receptor 1J1 Proteins 0.000 description 1
- 101000721115 Homo sapiens Olfactory receptor 4D11 Proteins 0.000 description 1
- 101000721070 Homo sapiens Olfactory receptor 4D9 Proteins 0.000 description 1
- 101000614008 Homo sapiens Olfactory receptor 4X1 Proteins 0.000 description 1
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 description 1
- 101000586097 Homo sapiens Olfactory receptor 5B21 Proteins 0.000 description 1
- 101000992266 Homo sapiens Olfactory receptor 5P3 Proteins 0.000 description 1
- 101001121117 Homo sapiens Olfactory receptor 8B4 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 101150024826 MET30 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100028178 Mas-related G-protein coupled receptor member X3 Human genes 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100036095 Olfactory receptor 14I1 Human genes 0.000 description 1
- 102100040769 Olfactory receptor 1F1 Human genes 0.000 description 1
- 102100032719 Olfactory receptor 1J1 Human genes 0.000 description 1
- 102100025146 Olfactory receptor 4D11 Human genes 0.000 description 1
- 102100025943 Olfactory receptor 4D9 Human genes 0.000 description 1
- 102100040570 Olfactory receptor 4X1 Human genes 0.000 description 1
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 1
- 102100030037 Olfactory receptor 5B21 Human genes 0.000 description 1
- 102100031850 Olfactory receptor 5P3 Human genes 0.000 description 1
- 102100026594 Olfactory receptor 8B4 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241001489223 Saccharomycodes Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical class CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960005469 hydroxocobalamin acetate Drugs 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000013521 mastic Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000007436 olfactory function Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003497 tellurium Chemical class 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 150000003544 thiamines Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/31—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention includes a water-soluble nucleoprotein, oligoribonucleic acid (oligo RNA), zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione, as well as a water-soluble nucleoprotein, oligo RNA, Composition for increasing blood dehydroepiandrosterone sulfate (DHEA-S) concentration, including odor, accepting zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione
- DHEA-S blood dehydroepiandrosterone sulfate
- the present invention relates to a composition for promoting the expression of a body gene and a composition for improving or preventing aging or stress.
- glutathione is an in vivo antioxidant substance present in each tissue of most organisms, and two types of reduced glutathione and oxidized glutathione are regulated by so-called redox cycle by glutathione peroxidase and glutathione reductase. It is known that the function as a substance is maintained (for example, refer patent document 2).
- glutathione can be used as an anti-oxidant substance in stress preventives and stress-improving foods by utilizing such functions of glutathione (see, for example, Patent Document 3 and Patent Document 4).
- sleep inducers and stress insomnia improving agents containing glutathione see, for example, Patent Document 5
- beverages containing a glutathione content of 0.01 to 1.0% by weight in beverages for example, Patent Documents 6
- beverages containing a wide variety of glutathione such as a glutathione-containing beverage whose total glutathione content is at least 50% by weight or more (for example, see Patent Document 7).
- DHEA-S is known as one of the hormones attracting attention as an index of rejuvenation (see, for example, Non-Patent Document 1).
- DHEA-S is an intermediate metabolite in male hormone synthesis, and is a sulfate conjugate of dehydroepiandrosterone (DHEA), also an intermediate metabolite, as both men and women grow in age from young to old. It is known to decrease and has a long blood half-life compared to DHEA, and no significant fluctuation is observed (see, for example, Patent Document 8), so it should be used as an objective index indicating the degree of aging. It is supposed to be possible. In addition, it has been confirmed that DHEA-S decreases in patients undergoing stress (see, for example, Non-Patent Document 2).
- Granular foods that have a rejuvenating effect that is mainly composed of ginseng ginseng and further contains gold and serpentine as food and pharmaceutical preparations intended to increase blood DHEA-S levels (see, for example, Patent Document 9) has been proposed. However, these raw materials are not easily available and are very expensive.
- autologous lymphocytes activated by proliferation by culturing lymphocytes collected from a subject in a culture solution containing anti-CD3 antibody and interleukin 2 immobilized on solid phase
- a preparation for increasing endogenous DHEA-S (eg, see Patent Document 8) has been proposed, but the preparation method is complicated and cannot be easily used.
- An object of the present invention is to provide a health drink or the like that can realize the effects of preventing and improving aging and stress.
- the present inventors have developed a novel, particularly from the viewpoint of reinforcing nutritional components that act in the nucleus.
- an improved beverage with a glutathione-containing yeast extract added to an existing health beverage containing water-soluble nucleoprotein, collagen, chondroitin, hyaluronic acid, vitamins, etc. Skin condition, general emotional disorder, autonomic nervous balance, and general health level are not limited to the additive effects of existing health drinks and glutathione, but synergistically improved I found out.
- the present invention provides [1] a health drink containing water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione, and [2] vitamins are vitamins.
- the health drink according to [1] above which contains one or more vitamin B groups selected from B 1 , vitamin B 2 , vitamin B 6 , vitamin B 12 and vitamin C;
- the glutathione-containing yeast extract is characterized in that a glutathione-containing yeast extract is used as the glutathione, and [4] the glutathione-containing yeast extract contains more oxidized glutathione than reduced glutathione. Addition of 6 to 60 mg per 1000 mL of health drink as described in [3] above, or [5] glutathione
- the present invention also provides [6] a composition for increasing blood DHEA-S concentration, comprising water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione. And [7] a composition for promoting expression of an olfactory receptor gene comprising water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione, [8] A composition for suppressing the expression of TNFRSF10C gene or TNFSF14 gene, comprising water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione, 9] Water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluro A composition for improving or preventing aging or stress characterized by containing acid, vitamins, and glutathione, and [10] vitamins include vitamin B
- composition according to any one of [6] to [9] above which contains one or more vitamin B groups selected from 12 and vitamin C; and [11] glutathione as glutathione
- the composition according to any one of the above [6] to [10], wherein the yeast extract is used, or the [12] glutathione-containing yeast extract contains more oxidized glutathione than reduced glutathione. It relates to the composition according to [11] above characterized.
- a composition comprising water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione is orally administered to a subject.
- DHEA-S concentration enhancing method and / or olfactory receptor gene expression promoting method composition comprising water soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione in blood Mention may be made of the use for the preparation of a DHEA-S concentration enhancer and / or an odorant receptor gene expression promoter.
- FIG. 1 It is a figure which shows an example which analyzed the condition of the skin of the face of the test subject of B group by "VISIA" about the item of a spot, a pore, a color nonuniformity, and an ultraviolet-ray spot.
- A shows the state of the facial skin of one subject before ingesting the b beverage
- (b) shows the state of the facial skin after the same subject ingested the b beverage for 5 weeks.
- VISIA subjects in groups A, B, and C reduced pores (improved) for improvement of facial skin before intake of any one of beverages a, b, and c and after intake for 5 weeks. And the correlation between color unevenness reduction (improvement).
- the average value of each group in the item of autonomic nerve balance by “Kiritsu Master” before and after taking any one beverage of a, b, and c for 5 weeks The improvement rate is shown.
- changes in blood DHEA-S concentration before and after taking any one beverage of a, b, and c for 5 weeks are shown.
- the vertical axis represents the blood DHEA-S concentration ( ⁇ g / dL).
- the average increase rate (%) of the DHEA-S concentration after ingestion of the DHEA-S concentration in blood of the subjects in each of the groups A, B, and C before the intake of each beverage is shown.
- Fig. 5 shows a Venn diagram for each of an increase in expression and a decrease in expression.
- A The probe which increased more than 1.2 times
- b is examining the probe which decreased more than 1.2 times.
- the genes belonging to “receptor activity” are extracted and listed in the molecular function of Gene Ontology (gene ontology).
- the genes belonging to “Receptor binding” in the molecular function of Gene Ontology are extracted and listed.
- FIG. 5 shows the increase or decrease in creatinine during the test period in identical twins who received beverages according to different patterns.
- Figure 5 shows the increase or decrease in total cholesterol during the study period in identical twins who received beverages according to different patterns.
- Figure 5 shows the increase or decrease in LDL cholesterol during the study period in identical twins that received beverages according to different patterns.
- the health drink of the present invention is not particularly limited as long as it is a drink containing water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione, and the method for producing such a drink is not particularly limited.
- each component can be added and mixed individually, or all components can be added and mixed at the same time, and a mixture of two or more components can be mixed separately to produce You can also.
- the above health drinks do not have a clear scientific or legal definition, but they contain ingredients that are supposed to improve health and improve health, and are distinguished from other drinks in terms of social recognition.
- GSH reduced glutathione
- GSSG oxidized glutathione
- GSH is a tripeptide having the structure of 5-L-glutamyl-L-cysteinylglycine
- GSSG is a GSH2 molecule. Is a compound bonded by an SS bond, and both are biosynthesized in vivo.
- GSSG is converted into GSH by glutathione reductase in vivo, it is similar to GSH even when GSSG is administered. It is said that the effect is expected.
- glutathione in the present invention any glutathione that can be used for food can be used.
- glutathione derived from marine microalgae such as Crypthecodinium cohnii (for example, JP-A-9-9 292), and the genus Saccharomyces, Hansenula, Endomycopus, Saccharomycodes, Nematospora, Candida, Tolropsis, Pretanomyces, Rhodotorula that are resistant to peroxides.
- Examples include glutathione derived from yeast belonging to the genus and glutathione derived from microorganisms belonging to the genus Escherichia, Alcaligenes or Proteus (see, for example, JP-A-8-70884). .
- yeast containing glutathione examples include yeasts belonging to the genus Saccharomyces cerevisiae (Saccharomyces char cerevisiae), Saccharomyces rouxii, Saccharomyces carlsbergensis, etc. ) (Candida utilis), Candida tropicalis, Candidaolipolytica, Candida flaveri, and other yeasts belonging to the genus Candida.
- a method for producing a glutathione-containing yeast containing glutathione at a high concentration
- a method of adding three kinds of amino acids for example, see JP-A-53-94089
- methionine in yeast culture In addition to the method of obtaining yeast cultivated by a method such as a method of increasing both the SAM content and glutathione content in yeast by adding glutamic acid to the medium (for example, see JP2009-017849A), mutation Yeast mutant strains in which at least a part of the DOA1 gene and at least a part of the MET30 gene have been deleted or mutated by treatment (for example, refer to JP 2010-029147 A), or belonging to the genus Candida, and polyene antibiotics are present Fermentation that can grow underneath and can contain large amounts of GSSG It can be mentioned a method using a mutant yeast strain such as a mutant strain (see JP 2003-284547 publication).
- a yeast mutant When using a yeast mutant, it is preferable to use a GSSG-rich mutant yeast with an increased GSSG production in terms of GSSG having higher stability in aqueous solution than GSH.
- Preferred examples include Uchiris 1453B5 (FERM P-18789), Candida utilis 1483A6 (FERM P-18790), and mutants thereof (see Japanese Patent Application Laid-Open No. 2003-284547).
- the above-mentioned microorganisms such as glutathione-containing yeast are preferably added as an extract (extract) of microorganisms such as glutathione-containing yeast because they can be easily added to foods and drinks.
- a glutathione-containing yeast extract 2 Examples thereof include yeast extract containing at least 8% by mass, preferably at least 8% by mass, more preferably at least 10% by mass, even more preferably at least 11% by mass, and more preferably at least 12% by mass.
- a method for producing such an extract of a microorganism such as glutathione-containing yeast a method of separating the water-soluble component after self-digestion, enzyme treatment or heat extraction (extraction with a solvent such as warm water) is known.
- a yeast extract containing 10% by weight or more of oxidized glutathione that belongs to the genus Candida can be grown in the presence of a polyene antibiotic, and can contain a large amount of oxidized glutathione (See, for example, JP-A-2004-283125).
- Commercially available products can be used as the glutathione-containing yeast extract, and examples of such commercially available products include Springer Hyp A (Bio Springer SA), Gluta yeast extract N (Kyowa Hakko Bio). it can.
- RNA ribonucleic acid
- yeast a well-known yeast such as yeast contains 20 to 50% of a fraction having a molecular weight of 1000 to 3000, and a fraction having a molecular weight of 1000 or less is an amount of a fraction having a molecular weight of 1000 to 3000
- Preferred examples include RNA that has been reduced in molecular weight to a higher level, for example, 30 to 50%.
- Methods for producing and obtaining the above oligo RNA include a method of reducing the molecular weight of the RNA isolated, extracted and purified from the yeast by enzymatic degradation or hydrolysis, a method of chemically or enzymatically synthesizing, or a commercially available product. And the like. Specifically, it is prepared by treating the 3 ′, 5′-phosphodiester bond of RNA by hydrolysis using a nuclease with heat stability.
- a suitable method for example, see JP-A-2007-23024 can be exemplified.
- the glutathione-rich yeast can be used as the oligo RNA source.
- yeast having a high glutathione content it can be used as oligo RNA and glutathione-containing oligo RNA containing 1% or more of glutathione (sometimes referred to as MATERNAL (registered trademark) RNA).
- glutathione sometimes referred to as MATERNAL (registered trademark) RNA.
- the water-soluble nucleoprotein is not particularly limited as long as it is a water-soluble nucleoprotein obtained by reducing the molecular weight of the nucleoprotein contained in the nucleus of a biological cell by enzymatic treatment or the like, but is not limited to ultraviolet irradiation or exposure to chemical substances. Is a small molecule having a molecular weight of 1000 to 3000 obtained by treating a nucleoprotein from a fish larvae with a nuclease and a protease in that the effect of effectively suppressing oxidative damage of the gene is confirmed.
- a water-soluble nucleoprotein containing 30% or more of the conjugated oligonucleotide / nucleoside and oligopeptide can be preferably exemplified.
- An example of such a water-soluble nucleoprotein is supernucleen.
- the hyaluronic acid is a kind of proteoglycan and has a basic structure in which a disaccharide unit in which the 1-position of ⁇ -D-glucuronic acid and the 3-position of ⁇ -DN-acetyl-glucosamine are linked is linked.
- Hyaluronic acid and its derivatives and their salts including hyaluronic acid, and low molecular hyaluronic acid or a degradation product of hyaluronic acid obtained by subjecting such hyaluronic acid to enzyme treatment using hyaluronidase or the like, or heat and pressure treatment
- hyaluronic acid derivative include acetylated hyaluronic acid (see JP-A-8-53501), sulfated hyaluronic acid (see JP-A-10-195107), and in vivo organic acids such as lactic acid.
- Hyaluronic acid substituted with see JP-A-6-16702 and crosslinked hyaluronic acid (JP-A-7-97401)
- Examples of the salts of hyaluronic acid and its derivatives include metal salts such as sodium salt, potassium salt, lithium salt, magnesium salt and calcium salt, bases such as lysine salt, arginine salt and histidine salt. And amino acid salts, ammonium salts, triethanolamine salts, and diisopropanolamine salts.
- Hyaluronic acids can be produced and obtained from methods such as separation, extraction from metabolites such as chicken crown, mammalian umbilical cord, fish, lactic acid bacteria and Streptococcus, chemical or enzymatic synthesis, and purchase of commercially available products.
- the publicly known methods such as the method of performing can be mentioned. Since solutions containing hyaluronic acid usually have high viscosity, there are many commercial products such as chicken crown extract and umbilical cord extract that decompose and / or purify hyaluronic acid depending on the type of product to be added and the required viscosity.
- hyaluronic acid HA-F manufactured by Kewpie Co., Ltd.
- sodium biohyaluronate manufactured by Shiseido Co., Ltd.
- hyaluronic acid FCH manufactured by Kibun Food Chemifa Co., Ltd.
- a preferred example is HA-F (manufactured by Kewpie Co., Ltd.).
- the chondroitin in the present invention is a kind of glycosaminoglycan (mucopolysaccharide), and sulfate is added to a sugar chain in which a disaccharide of D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc) is repeated.
- GlcA D-glucuronic acid
- GalNAc N-acetyl-D-galactosamine
- Chondroitin and derivatives thereof having a combined structure as a basic structure and chondroitins which are salts thereof include chondroitin, such as chondroitin-4-sulfate (chondroitin sulfate A), dermatan sulfate (chondroitin sulfate B), chondroitin-6 -Sulfuric acid (chondroitin sulfate C), chondroitin sulfate D, chondroitin-4, 6-sulfuric acid (chondroitin sulfate E) can be mentioned.
- Chondroitin derivatives include chondroitin and reducing sugars such as glucose, galactose, maltose, and lactose.
- Condensates and aryl ethers examples thereof include derivatives of tellurium, phosphoric acid ester, sulfuric acid ester and the like, and examples of chondroitin and its salt include alkali metal salts such as sodium salt and potassium salt, inorganic salts such as hydrochloride, sulfate and ammonium salt, Examples thereof include organic salts such as lactate, acetate, and triethanolamine salt.
- Methods for producing and obtaining chondroitin include separation and extraction from chondroitin-containing natural products such as shark cartilage and shark fin extract, methods of chemical or enzymatic synthesis, and methods of purchasing commercially available products.
- chondroitin-containing mucopolysaccharide protein complexes such as “costal cartilage extract (70)” (manufactured by Nakahara Co., Ltd.).
- the collagen according to the present invention has an extracellular structure in tissues such as skin tissue, cartilage tissue, bone tissue, vascular tissue, organ, and tendon having a repeating structure having a peptide fragment of “-glycine-amino acid-amino acid-” as a unit.
- Fibrous proteins constituting the matrix, and hydrolysates thereof (collagen peptides), and derivatives thereof are included, and examples of collagen derivatives include atheroses, acylates, and succinylates of collagen and hydrolysates thereof. be able to. Since the molecular weight of general collagen is about tens of thousands to 300,000 and is usually insoluble, it is common to use a water-soluble collagen hydrolyzate (collagen peptide).
- a collagen hydrolyzate for example, after washing the dermis of animals such as pigs and cattle or crushing bone, it contains collagen such as alkali treatment, neutralization, degreasing, mineral removal, etc.
- a known method such as a method of decomposing the extract with an enzyme, etc., sterilizing after filtration, spray drying, and powdering can be used.
- a commercially available product can be used separately.
- Zinc in the present invention is not particularly limited as long as it can be added in a form that can be used in foods, and can be administered in a form such as zinc gluconate, zinc sulfate, and edible zinc yeast. It is preferable to add as edible zinc-containing yeast, which is said to have a higher absorption rate, and it is desirable to use yeast containing 2% by mass, preferably 3% by mass, more preferably 4% by mass or more as zinc. Commercially available products include edible yeasts (containing zinc) such as zinc yeast (manufactured by GROW), mineral yeast-Zn (manufactured by Oriental Yeast), and zinc yeast (manufactured by Bio Springer). (Made by GROW) can be mentioned suitably.
- the vitamins contained in the health drink of the present invention are not particularly limited as long as they are vitamins or derivatives thereof, or salts thereof that can achieve the effects of the present invention.
- vitamin C ascorbic acid
- Vitamin B 1 thiamine
- vitamin B 2 riboflavin
- vitamin B 6 pyridoxine
- vitamin B 12 cobalamin
- vitamin C or salts thereof include calcium ascorbate, ascorbine
- vitamin B 1 derivatives or salts thereof include thiamine hydrochloride, thiamine nitrate, bis-thiamine nitrate, thiamine dicetyl sulfate ester salt, fursultiamine hydrochloride, octothiamine, benfotiamine and the like.
- a vitamin B 2 derivative or Examples of these salts include riboflavin butyrate and sodium riboflavin phosphate
- examples of vitamin B 6 derivatives or salts thereof include pyridoxine hydrochloride, pyridoxal (pyridoxal phosphate), and pyridoxamine.
- vitamin B 12 or a derivative thereof or a salt thereof examples include cyanocobalamin, hydroxocobalamin, hydroxocobalamin acetate, hydroxocobalamin hydrochloride, methylcobalamin, and adenosylcobalamin.
- the vitamins are preferably contained in two or more types, more preferably in three or more types, and even more preferably in four or more types.
- Specific combinations include vitamin C and vitamin B 1 , vitamin C and vitamin B 2 , vitamin C and vitamin B 6 , vitamin C and vitamin B 12 , vitamin C and vitamin B 1 and B 2 , vitamin C and vitamin B 1 and B 6 , vitamin C and vitamin B 1 and B 12 , vitamin C and vitamin B 2 and B 6 , vitamin C and vitamin B 2 and B 12 , vitamin C and vitamin B 6 and B 12 , vitamin C and vitamin B 1 and B 2 and B 6 , vitamin C and vitamins B 1 and B 6 and B 12 , vitamin C and vitamins B 1 and B 6 and B 12 , vitamin C and vitamins B 1 and B 6 and B 12 , vitamin C and vitamins B 2 and B 6 and B 12 , and vitamin C and it can be exemplified a combination of vitamin B 1 and B 2 and B 6 and B 12.
- the addition amount of each of the above components in the health drink of the present invention is not particularly limited.
- 6 to 60 mg of glutathione (0.05 to 0.5 g of glutathione-containing microbial extract), oligo per 1000 mL of the health drink of the present invention RNA 0.1-5 g, water-soluble nucleoprotein 0.5-10 g, zinc yeast 0.1-3 g, collagen 50-150 g, chondroitin 0.01-0.5 g, hyaluronic acid 0.01-0.5 g, vitamin C5
- glutathione 0.1 to 0.35 g of a glutathione-containing microbial extract
- the beverage of the present invention is preferably taken in the above-mentioned prescription three times a day, 20 mL each after morning, noon, and evening meals, since the effect of the present invention is noticeable after 5 weeks. Even when the frequency is appropriately increased or decreased, the same effect can be obtained by drinking for a long time.
- the intake of the health drink of the present invention can be determined subjectively by a pharmacologist and a clinician in the technical field using a known method or based on the judgment of the person himself / herself. For example, the situation of the intake person is observed until the degree of feeling the stress decreases until the intake DHEA-S concentration is increased or until the total cholesterol level and LDL cholesterol level are decreased.
- the intake and frequency of the health drink of the present invention can be appropriately increased or decreased.
- the beverage of the present invention can be mixed with sugar, sugar alcohol, sweetener, etc. in order to improve the taste of the beverage in consideration of consumer preference.
- sugar alcohols include xylitol, sorbitol, maltitol, erythritol, and mannitol.
- sweeteners include acesulfame potassium.
- Sucralose, neotame, saccharin, aspartame, stevia, and saccharides, sugar alcohols, and sweeteners can be added alone or in combination of two or more.
- flavors can be added as appropriate in order to mask the odor of animal raw material products or improve the flavor of beverages.
- foods such as honey can be added.
- the beverage of the present invention can be further blended with a preservative and an emulsifier as necessary in consideration of drinking comfort and storage, and examples of the preservative include sodium benzoate and sorbic acid.
- examples of the preservative include sodium benzoate and sorbic acid.
- sodium benzoate is preferable, and examples of the emulsifier include glycerin fatty acid ester emulsifiers and sucrose fatty acid ester emulsifiers, and preservatives and emulsifiers can be used alone or in combination of two or more. .
- the beverage of the present invention can be further blended with a gelling agent in order to improve the drinking comfort and to be easily taken by an ingestor with low swallowing ability.
- a gelling agent such as gelatin, pectin, agar, carrageenan, gellan gum, glucomannan, locust bean gum and the like, and one or more of these gelling agents can be added. .
- the composition of the present invention includes a water-soluble nucleoprotein, oligo RNA, zinc, collagen, chondroitin, hyaluronic acid, vitamins, and glutathione-containing yeast, and increases blood DHEA-S concentration.
- the composition of the present invention has the effect of increasing the blood DHEA-S concentration, promoting the expression of the odorant receptor gene, and further promoting the expression of the growth hormone gene in foods and beverages and food materials.
- the dosage form of the aging or stress improvement and / or prevention agent and the stress improvement and / or prevention food and beverage additive is not particularly limited, and may be a solid preparation or liquid preparation using an appropriate carrier. it can.
- an effective amount thereof can be added and mixed in the raw material production stage of the food and drink and / or the stage of the manufactured product.
- the effects of ingesting the beverage or composition of the present invention can include aging improvement / prevention effects and stress improvement / prevention effects.
- the aging improvement / prevention effects include skin aging improvement, blood Increase in DHEA-S concentration, decrease in LDL cholesterol in blood, promotion of odorant receptor gene expression and / or growth hormone expression, and stress relief / feeling of good sleep
- subjective things such as mood
- objective things that can be measured using measuring instruments such as general emotional disorders, autonomic balance and function, and / or improvement effects on general health. it can.
- the skin aging is not particularly limited as long as it is skin aging, whether it is physiological aging due to aging or photoaging due to irradiation of ultraviolet rays, and specifically, pores that can be observed
- One type or two or more types selected from blots, uneven color, and ultraviolet blots can be exemplified.
- the effects of preventing and improving skin aging include the reduction of pores that can be observed by subjects after ingestion for a specified period, the reduction of stains, the reduction of color unevenness, the reduction of UV stains, and the skin condition in comprehensive evaluation.
- VISIA Complexion Analysis (made by Canfield), which is a skin image analysis counseling system that is superior in that it can be analyzed at the same site after the second time by adjusting can do.
- VISIA VISIA Complexion Analysis
- Canfield a skin image analysis counseling system that is superior in that it can be analyzed at the same site after the second time by adjusting can do.
- the evaluation can also be performed by performing a skin elasticity test using a skin grip meter AS-GP1 (manufactured by Asahi Biomed).
- Examples of the improvement effect on the balance and function of the autonomic nerve include improvement of the balance and function of the subject's autonomic nerve after ingestion for a predetermined period.
- the method of analyzing using the autonomic nerve reflex real-time monitor software “Kiritsu Master” (manufactured by Crosswell Co., Ltd.), which can diagnose the autonomic nerve function, can be exemplified. This method may lead to a drop in orthostatic blood pressure when the autonomic nerves cannot cope with the stress caused by standing up.However, if the body and mind are healthy, the sympathetic nerve is habitually raised during standing up and the peripheral blood vessels are contracted.
- Examples of the improvement effect on the general health level include an improvement of the general health level of the subject after ingesting the beverage for a predetermined period, and a method for confirming the effect is a simple measurement in a short time. It is suitable for understanding the health of the subject and confirming the treatment effect, and is said to be capable of accurate measurement with high reproducibility.
- AmSAT (HC) -HC AutoMastic System for Analysis Therapy-Holistic Concept : Fully automatic skin resistance measurement system
- 22 patterns of current values are measured from 6 electrodes on the forehead, both hands, and both feet. The obtained value is compared with the data bank information in the system and calculated by an algorithm to obtain data.
- data can be obtained by displaying the deviation degree from the ideal value of the measurement result at a maximum of ⁇ 100% at 67 points of the whole body by a special algorithm including waveform analysis.
- it can be evaluated that it improved when the deviation degree became small from the measured value ideal value.
- Examples of the effect on the blood DHEA-S concentration include an increase in the blood DHEA-S concentration of the subject after drinking for a predetermined period.
- Examples of the method for measuring the blood DHEA-S concentration include a radioimmunoassay method (RIA) and a tube solid phase method.
- RIA radioimmunoassay method
- a tube solid phase method When the blood DHEA-S concentration in the subject was significantly increased compared to the blood DHEA-S concentration in the subject before the start of intake, it was evaluated that there was an effect of taking a specific health drink. be able to.
- Examples of the effect on the blood LDL cholesterol concentration include a decrease in the blood LDL cholesterol concentration of the subject after drinking for a predetermined period.
- Test drink A double-blind test was conducted using the following three types of test beverages. Table 1 below shows an outline of prescriptions for a beverage, b beverage, and c beverage.
- a beverage was prepared based on the formulation of a conventional product (nucleic acid drink: natural DN collagen: manufactured by Four Days Co., Ltd.).
- the b beverage is a beverage of the present invention prepared by adding a yeast extract containing a high glutathione content to the conventional beverage a beverage.
- An example in which oligo RNA and glutathione-containing yeast are separately mixed is shown in Table 1, but may be prepared using MATERNAL (registered trademark) RNA having an equivalent composition.
- c drink is a drink for examining the effect only when glutathione is added, excluding raw materials and emulsifiers considered to be functional ingredients from conventional a drink, and the texture of a drink and b drink Liquid dextrin was added to bring it close to the surface.
- the sweetener when liquid dextrin is added instead of the collagen peptide, the sweetener is increased as compared with the beverage a and beverage b, and therefore the sweetener (sucralose) is excluded. Moreover, a fragrance
- test subjects were 60 healthy men (age 53.5 ⁇ 2.5 years, average BMI 22.3 kg / m 2 ). Based on prior health checkups, normal blood glucose level (glucose, HbA1C), liver function (GOT, GPT, ⁇ -GTP), pancreatic function (amylase), uric acid level, renal function (creatinine) in non-smoking subjects After confirming this, the subjects were a subject (group A) who ingests a beverage (conventional product), a subject (group B) who ingests beverage b (the beverage of the present invention), and a beverage (active ingredient of conventional products).
- group A who ingests a beverage
- group B who ingests beverage b (the beverage of the present invention)
- a beverage active ingredient of conventional products
- FIG. 1 (a) shows the state of the skin of the face of the subject before ingesting the b beverage
- FIG. 1 (b) shows the state of the skin of the face after ingesting the b beverage for the same subject for 5 weeks.
- the numbers on the right side of each item are numerical values for blots, pores, ultraviolet blots, and color unevenness, indicating that the numbers were improved as the numbers decreased. The improvement situation could be confirmed from the photographs of the respective items in FIGS. 1 (a) and (b).
- AMSAT Amsat
- HC Automatic Mastic System for Analysis Therapy-Holistic Concept: fully automatic skin resistance measurement system.
- Each subject connected a total of 6 electrodes, forehead, hands, and legs, and 22 patterns of current values were measured in 17 seconds.
- the measured values are compared with the data bank information in the system and distributed to the whole body part, spinal cord, and nervous system with a special algorithm including waveform analysis, and the deviation from the ideal value of the measurement result is maximized at 74 parts of the whole body.
- Group B showed advantageous effects compared to Group A and Group C in the thyroid gland, rectum, sensory organ, pharynx, thigh, hip joint, and cecum.
- Expression fluctuation genes were extracted by statistical analysis using the blood samples of the subjects in groups A, B, and C. Using the data detected using the microarray assay, the normalized expression data was subjected to the calculation of the P value by the significance test and the cutoff based on the expression ratio. For the significant difference test between the two groups, SAM t-test used for the test between the two groups in the microarray data was used. Logarithmic expression ratio between the two groups is 0.263 or more (log expression ratio is 1.23 or more) for the probes whose P value calculated in the combination of comparison before and after drinking is less than 0.05. A probe showing a significant increase in expression) and a probe showing a log expression ratio between two groups of -0.263 or less (the expression ratio is 0.8333 times or less) as a significant expression lowering probe As a cut-off passage probe.
- a gene name underlined is a probe related to a receptor having increased expression
- a gene name not underlined is a probe related to a receptor having decreased expression.
- MRGPRX3, OR14I1, OR1F1, OR1J1, OR4D11, OR4D9, OR4X1, OR51E2, OR5B21, OR5P3, and OR8B4 are genes encoding olfactory receptor proteins, and odor It was confirmed that expression was promoted for the olfactory receptor protein.
- TNFRSF10C which is a TNF receptor
- TNFSF14 which is a TNF ligand
- FIG. 8 shows a list of the genes belonging to “Receptor binding” extracted from the molecular function of gene ontology among the probes that showed specific fluctuations in group B.
- a gene name that is underlined is a probe related to a ligand with increased expression
- a gene name that is not underlined is a probe related to a ligand with decreased expression. It was also confirmed that expression was promoted for the GH1 growth hormone gene. Therefore, it can be said that the ingestion of the beverage of the present invention has been confirmed to have an effect of preventing and improving aging.
- test period was 101 days in total: 5 weeks in the previous period + 31 days in the rest period + 5 weeks in the latter period.
- Total cholesterol concentration [Sister] and [Sister] measured the total blood cholesterol concentration (mg / dL) several times during the test period by the enzyme method (contract measurement by Mitsubishi Chemical Rulece). The result is shown in FIG. [Sister] had no decrease in blood total cholesterol concentration during the period of taking a drink and the rest period of 31 days, but in the latter 5 weeks after taking the b drink after the rest period. The total cholesterol concentration was remarkably reduced (see dotted line ⁇ part in FIG. 11). In [Sister], the total cholesterol concentration decreased in the first 5 weeks of ingestion of the b beverage (see the solid line in FIG. 11), and did not increase during the 31-day rest period, but also in the later 5 weeks of ingestion of the a beverage. A decreasing trend was observed.
- LDL cholesterol concentration [Sister] and [Sister] measured blood LDL cholesterol concentration (mg / dL) several times during the test period by the enzyme method (contract measurement by Mitsubishi Chemical Rulece). The result is shown in FIG. [Sister] had no decrease in blood LDL cholesterol level during the period of taking a drink and the rest period for 31 days, but in the latter 5 weeks of taking b drink after the rest period. LDL cholesterol concentration decreased (see dotted line ⁇ part in FIG. 12). In [Sister], the LDL cholesterol concentration decreased in the first 5 weeks of ingestion of the b beverage (see the solid line in FIG.
- pentose phosphate pathway (pentose phosphate fundamental pathway) is one of the glucose metabolism pathways and is an important pathway that metabolizes glucose and plays a major role in supplying NADPH, which is a reducing power essential for fatty acid biosynthesis. .
- NADPH a reducing power essential for fatty acid biosynthesis.
- the TCA circuit is an important circuit as a metabolic circuit for sugars, fatty acids, amino acids and the like. As is clear from Table 4 above, it was confirmed that the expression of the related gene was increased in the TCA circuit, and it was confirmed that the intake of b beverage favors energy production.
Abstract
Description
(試験飲料)
以下の3種類の試験飲料を用いて二重盲検試験を行った。a飲料、b飲料、c飲料の処方の概要を以下の表1に示す。
被験者は、健常者の男性60名(年齢53.5±2.5歳、平均BMI22.3kg/m2)であった。事前の健康診断により、非喫煙の被験者で、血糖値(グルコース、HbA1C)、肝機能(GOT、GPT、γ-GTP)、膵機能(アミラーゼ)、尿酸値、腎機能(クレアチニン)が正常であることを確認後、被験者を、a飲料(従来品)を摂取する被験者(A群)と、b飲料(本発明の飲料)を摂取する被験者(B群)と、c飲料(従来品の有効成分を除きグルタチオン含有酵母を添加した飲料)を摂取する被験者(C群)との3群に、20名ずつ無作為に分類し二重盲検試験を行った。被験者は、いずれの飲料を摂取しているかを知らされることなく、上記飲料のいずれかを20mLずつ、朝、昼、晩の一日3回5週間の試験期間中に摂取するよう指示された。なお、試験期間中は、他のサプリメント等の摂取は控えるように指示されたが、特に厳格な食事制限は行わず、通常通りの生活をおくるように指導された。
本発明の飲料が皮膚の老化の予防・改善効果を有しているか否かを確認するために、各群の被験者につき、摂取開始前と摂取5週間後の顔の皮膚の状態を、皮膚画像解析カウンセリングシステムである「VISIA」を用いて、しみ、毛穴、色むら、紫外線しみ、ポルフィリン、しわの6項目について分析した。各項目と6項目の総合的な判定について、統計解析ソフトJMP8を使用し、ウィルコクスンの符号付順位検定により解析した。結果を以下の表2並びに図1(a)及び(b)に示す。
本発明の飲料が総合感情障害における効果を有しているか否かを確認するために、各群の被験者は、摂取開始前と摂取5週間後に、POMS日本版調査票に回答した。ウィルコクスンの符号付順位検定を用いた結果を以下の表3に示す。なお、B群の被験者において、一部の項目の未記入者がいたため、n=19となっている項目がある。
本発明の飲料が自律神経機能やバランスにおいて改善効果を有しているかどうかを確認するために、各群の被験者につき、摂取開始前と摂取5週間後に、「きりつ名人」を用いて評価が行われた。「きりつ名人」の取扱説明書の指示に従い、心拍数の測定のため両手首にクリップを止め、胸に電極を貼り、血圧を測定するために腕にカフを巻き、パルスオキシメータを指に装着した。各被験者は、座位にて安静を3分間維持した後、音声ガイダンスにしたがって起立するよう指示された。起立後約3分30秒測定が継続された。オシロメトリック法による血圧測定は、座位安静1分後から毎分6回測定され、自律神経は30秒後から1拍ごとに解析された。ウィルコクスンの符号付順位検定の下側検定を行った結果、自律神経バランスの項目において、b飲料を摂取した被験者において87.4%の向上がみられ(図3参照)、b飲料の摂取が、日常生活において衰えが問題となる自律神経機能やバランス感覚において、a飲料やc飲料との相加的効果を超える相乗的効果をもたらすことが確認された。
本発明の飲料が被験者の全身的な健康度において改善効果を有しているかどうかを確認するために、各群の被験者につき、摂取開始前と摂取5週間後に、AMSAT(アムサット)-HC(Auto Mastic System for Analysis Therapy - Holistic Concept:全自動皮膚抵抗値測定システム)を用いて解析した。各被験者は額・両手・両足の計6極の電極をつなぎ、22パターンの電流値が17秒で計測された。計測された値は、システムにおけるデータバンク情報と比較され、波形解析を含めた特殊なアルゴリズムで全身の部位や脊髄、神経系にも振り分けられ全身74箇所について、測定結果理想値から逸脱度を最大±100%で表示されたが、甲状腺、直腸、感覚器、咽頭、大腿部、股関節、盲腸において、B群は、A群やC群と比較して有利な効果が見られた。
本発明の飲料が血液成分についていかなる作用を及ぼしているかを確認するために、血液検査を行った。RIA法により血中DHEA-S濃度を測定したところ、b飲料を摂取した被験者の血中DHEA-S濃度に変化がみられため、詳しく検討した。B群は、A群、C群と比較してb飲料を摂取することでt検定により有意に血中DHEA-S濃度が増加していた(p=0.0001)(図4参照)。なお、各被験者の血中DHEA-S濃度は50代男性の正常範囲内である53~342μg/dLであった。また、各群の被験者の血中DHEA-S濃度の各飲料摂取前に対する摂取後のDHEA-S濃度の平均増加率(縦軸)を図5に示す。b飲料の摂取が、DHEA-S濃度の増加を顕著にもたらすことが確認された。
A群、B群、C群の各被験者の血液試料を用い、統計解析による発現変動遺伝子(プローブ)の抽出を行った。マイクロアレイアッセイを使用して検出されたデータを用い、正規化済みの発現データを対象に有意差検定によるP値の算出と発現比に基づくカットオフを実施した。2群間の有意差検定は、マイクロアレイデータにおける2群間検定に用いられるSAM t-testを使用した。飲料の摂取前後の比較の組合せにおいてそれぞれ算出されたP値が、0.05未満となったプローブについて、2群間の対数発現比がlog ratioで0.263以上(発現比として、1.2倍以上)を示すプローブを有意な発現上昇プローブとし、2群間の対数発現比がlog ratio で-0.263以下(発現比として、0.8333倍以下)を示すプローブを有意な発現低下プローブとしてカットオフ通過プローブとした。
b飲料を摂取したB群の被験者において、皮膚の状態、総合感情障害、自律神経バランス、全身的な健康度における試験において、また、DHEA-Sの血中濃度、臭嗅受容体遺伝子発現等の生化学的指標において、a飲料の効果とc飲料の効果との相加効果にとどまらず、相乗的な改善効果が被験者にもたらされることが確認された。
一卵性双子の女性2人[姉](the first twin sister:FTS)と[妹](the second twin sister:STS)(姉BMI34.9、妹BMI33.6)が被験者となり試験を行った。[姉]は、上記実施例1で使用したa飲料を20mLずつ、朝、昼、晩の一日3回5週間摂取し、31日の休止期間後、上記実施例1で使用したb飲料を20mLずつ、朝、昼、晩の一日3回5週間摂取するよう指示された。[妹]は、b飲料を20mLずつ、朝、昼、晩の一日3回5週間摂取し、31日間の休止期間後、a飲料を20mLずつ、朝、昼、晩の一日3回5週間摂取するよう指示された。前期5週間+31日の休止期間+後期5週間の合計101日間を試験期間とした。
上記一卵性双子の[姉]と[妹]は、試験期間中に左と右の頬それぞれについてスキングリップメーターAS-GP1(朝日バイオメッド社製)を用い、製造者作成の取扱い説明書に基づき、複数回の肌弾力試験を行った。その結果を図9((a)及び(b))に示す。[姉]はa飲料を摂取している期間及びその後の31日間の休止期間中には、肌弾力性の増加はみられなかったが、休止期間後にb飲料を摂取した後期5週間において左頬(実線)、右頬(点線)ともに肌弾力性が顕著に増加した(図9(a)参照)。[妹]は、b飲料を摂取した前期5週間において肌弾力性が増加したが、31日間の休止期間において弾力性は減少し、a飲料を摂取した5週間においてはほとんど変化がみられなかった(図9(b)参照)。
上記[姉]と[妹]は、試験期間中に血中クレアチニン濃度(mg/dL)を酵素法(クレアチナーゼ-サルコシンオキシダーゼ-ペルオキシダーゼ法)(三菱化学メディエンスにて委託測定)により複数回測定した。その結果を図10に示す。[姉]は点線、[妹]は実線で示される。[姉]はa飲料を摂取した前期5週間及びその後の31日間の休止期間中には、血中クレアチニン濃度の減少はみられなかったが、休止期間後にb飲料を摂取した後期5週間において血中クレアチニン濃度が顕著に減少した(図10点線→部分参照)。[妹]は、b飲料を摂取した前期5週間において血中クレアチニン濃度が減少したが(図10実線→部分参照)、31日間の休止期間において増加し、a飲料を摂取した後期5週間においては変化がみられなかった(図10実線参照)。慢性腎臓病や高血圧患者においてクレアチニンが高濃度であることが知られており(Annals of Internal Medicine,Vol. 141 No. 12,929-937 及びArch. Intern. Med. Vol 161,2001, 1207-1216)、本発明の飲料が、高血圧の改善や慢性腎臓病の改善に効果があることが示唆された。
上記[姉]と[妹]は、試験期間中に血中総コレステロール濃度(mg/dL)を酵素法(三菱化学メディエンスにて委託測定)により複数回測定した。その結果を図11に示す。[姉]はa飲料を摂取している期間及びその後の31日間の休止期間中には、血中総コレステロール濃度の減少はみられなかったが、休止期間後にb飲料を摂取した後期5週間において総コレステロール濃度が顕著に減少した(図11点線→部分参照)。[妹]は、b飲料を摂取した前期5週間において総コレステロール濃度が減少し(図11実線→部分参照)、31日間の休止期間においても増加せず、a飲料を摂取した後期5週間においても減少傾向がみられた。
上記[姉]と[妹]は、試験期間中に血中LDLコレステロール濃度(mg/dL)を酵素法(三菱化学メディエンスにて委託測定)により複数回測定した。その結果を図12に示す。[姉]はa飲料を摂取している期間及びその後の31日間の休止期間中には、血中LDLコレステロール濃度の減少はみられなかったが、休止期間後にb飲料を摂取した後期5週間においてLDLコレステロール濃度が減少した(図12点線→部分参照)。[妹]は、b飲料を摂取した前期5週間においてLDLコレステロール濃度が減少し(図12実線→部分参照)、31日間の休止期間においても増加しなかったが、a飲料を摂取した後期5週間においてはわずかに増加傾向がみられた。上記総コレステロール濃度の結果をあわせ、本発明の飲料は、いわゆるメタボリック症状に対して効果を有することが示唆された。
上記[妹]に睡眠状況について問診したところ、[妹]がb飲料を摂取した際に、[妹]のみが元々持っていた睡眠状況の問題が改善された。具体的には、夜間に咳が出たり、大きないびきをかいたりすることが少なくなったとの回答を得た。この問題は、一卵性双子でありながら妹に特異的であったが、a飲料を摂取した際には改善が認められなかった。
本発明の飲料が被験者の全身的な健康度において改善効果を有しているかどうかを確認するために、上記[姉]と[妹]につき、摂取開始前と摂取5週間後に、AMSATを用いて上記実施例1に記載されている手順と同様の手順にて解析した。a飲料を摂取した前と後に解析を行った場合、[姉]と[妹]いずれにおいても顕著な数値の変化は見られなかったが(図13(a)及び(b)参照)、b飲料を摂取した前と期間後に解析を行った場合、[姉]と[妹]いずれにおいても74の検査項目のほとんどにおいて摂取後に顕著な数値の減少を示し、理想状態とされる0に近い数字となった(図14(a)及び(b)参照)。このことは、AMSATを用いた全身的な健康度の評価において、細胞間質の軟化が抑制され炎症性の改善効果がみられたことを示している。
b飲料を摂取した上記双子の[姉]と[妹]及び、実施例1においてb飲料を摂取したB群の被検者男性群の血液試料を用い、実施例1の遺伝子発現調査において行ったのと同様の手順で統計解析による発現変動遺伝子(プローブ)の抽出を行った。b飲料の摂取前後で発現変動が1.2倍以上増加又は1.2倍以上減少がみとめられたプローブについて、被験者の属する群においてどのようにプローブの発現変動が重複しているかを、発現増加と減少のそれぞれについてベン図として表記した(図15(a)(b)参照)。双子の被験者と男性の被験者の両方において発現が増加していたプローブ数は9であった。有意に増加している9種類のプローブには(図15(中央重なり部分)参照)、臭嗅受容体(olfactory receptor)タンパク質をコードする遺伝子OR14I1が含まれており、臭嗅受容体に関する遺伝子が活性化されていたことは、上記AMSATを用いた全身的な健康度の評価において、感覚器における数値も含めて有利な効果がみられたこととも一致する。
肥満傾向にある双子のa飲料とb飲料の摂取量は、体重1kgあたり姉0.63mL/kg/日、妹0.68mL/kg/日であって、実施例1における男子の摂取量よりも少なくなっている。少ない摂取量であっても、5週間本発明のb飲料を摂取することで、血中クレアチニン濃度の減少、総コレステロールの減少、LDLコレステロールの減少、睡眠状況の改善等、老化やストレスの予防・改善効果がもたらされることが確認された。また、発現遺伝子解析においても、b飲料の摂取は健康状態の向上に寄与することがわかった。b飲料の摂取は、肥満傾向の体質で起こる炎症反応を抑制することで細胞のストレスを軽減し、基礎代謝を活発にすることで肥満傾向の改善に効果がある。
Claims (12)
- 水溶性核タンパク質、オリゴRNA、亜鉛、コラーゲン、コンドロイチン、ヒアルロン酸、ビタミン類、及びグルタチオンを含むことを特徴とする健康飲料。
- ビタミン類が、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12から選ばれる1又は2種類以上のビタミンB群と、ビタミンCとを含むことを特徴とする請求項1記載の健康飲料。
- グルタチオンとして、グルタチオン含有酵母抽出物を用いることを特徴とする請求項1又は2記載の健康飲料。
- グルタチオン含有酵母抽出物が、還元型グルタチオンよりも酸化型グルタチオンを多く含むことを特徴とする請求項3記載の健康飲料。
- グルタチオンとして、1000mLあたり6~60mgを添加することを特徴とする請求項1~4のいずれか記載の健康飲料。
- 水溶性核タンパク質、オリゴRNA、亜鉛、コラーゲン、コンドロイチン、ヒアルロン酸、ビタミン類、及びグルタチオンを含むことを特徴とする血中デヒドロエピアンドロステロンサルフェート(DHEA-S)濃度を増加させるための組成物。
- 水溶性核タンパク質、オリゴRNA、亜鉛、コラーゲン、コンドロイチン、ヒアルロン酸、ビタミン類、及びグルタチオンを含むことを特徴とする臭嗅受容体遺伝子の発現を促進するための組成物。
- 水溶性核タンパク質、オリゴRNA、亜鉛、コラーゲン、コンドロイチン、ヒアルロン酸、ビタミン類、及びグルタチオンを含むことを特徴とするTNFRSF10C遺伝子又はTNFSF14遺伝子の発現を抑制するための組成物。
- 水溶性核タンパク質、オリゴRNA、亜鉛、コラーゲン、コンドロイチン、ヒアルロン酸、ビタミン類、及びグルタチオンを含むことを特徴とする老化若しくはストレスを改善又は予防するための組成物。
- ビタミン類が、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12から選ばれる1又は2種類以上のビタミンB群と、ビタミンCとを含むことを特徴とする請求項6~9のいずれか記載の組成物。
- グルタチオンとして、グルタチオン含有酵母抽出物を用いることを特徴とする請求項6~10のいずれか記載の組成物。
- グルタチオン含有酵母抽出物が、還元型グルタチオンよりも酸化型グルタチオンを多く含むことを特徴とする請求項11記載の組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013538440A JP6138048B2 (ja) | 2011-10-12 | 2012-10-11 | システインペプチド含有健康飲料 |
US14/350,519 US20140302171A1 (en) | 2011-10-12 | 2012-10-11 | Cysteine Peptide-Containing Health Drink |
CN201280049522.XA CN103874431A (zh) | 2011-10-12 | 2012-10-11 | 含有谷胱甘肽的保健饮料 |
KR1020147007511A KR101656224B1 (ko) | 2011-10-12 | 2012-10-11 | 시스테인 펩티드 함유 건강 음료 |
US16/034,949 US20180344874A1 (en) | 2011-10-12 | 2018-07-13 | Cysteine Peptide-Containing Health Drink |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-225356 | 2011-10-12 | ||
JP2011225356 | 2011-10-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/350,519 A-371-Of-International US20140302171A1 (en) | 2011-10-12 | 2012-10-11 | Cysteine Peptide-Containing Health Drink |
US16/034,949 Continuation US20180344874A1 (en) | 2011-10-12 | 2018-07-13 | Cysteine Peptide-Containing Health Drink |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013054525A1 true WO2013054525A1 (ja) | 2013-04-18 |
Family
ID=48081592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/006525 WO2013054525A1 (ja) | 2011-10-12 | 2012-10-11 | グルタチオン含有健康飲料 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20140302171A1 (ja) |
JP (1) | JP6138048B2 (ja) |
KR (1) | KR101656224B1 (ja) |
CN (2) | CN108354102A (ja) |
HK (1) | HK1254518A1 (ja) |
WO (1) | WO2013054525A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017009427A (ja) * | 2015-06-22 | 2017-01-12 | 株式会社ファンケル | 頭皮の圧縮応力の評価方法 |
JP2019001766A (ja) * | 2017-06-20 | 2019-01-10 | 国立大学法人北海道大学 | 脂質吸収抑制用剤 |
JP2019131517A (ja) * | 2018-02-01 | 2019-08-08 | エスエス製薬株式会社 | 内服液 |
WO2020027012A1 (ja) * | 2018-07-30 | 2020-02-06 | 味の素株式会社 | 大豆蛋白質飲料 |
WO2021182534A1 (ja) * | 2020-03-12 | 2021-09-16 | フォーデイズ株式会社 | 水溶性核タンパクを含有する健康飲料 |
JP7180935B1 (ja) | 2021-09-14 | 2022-11-30 | プラス・レイ株式会社 | 液状飲料組成物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105325821A (zh) * | 2014-06-27 | 2016-02-17 | 北大方正集团有限公司 | 一种健康功能型饮料及其制备方法 |
ES2638195B1 (es) | 2016-04-18 | 2018-08-02 | Bioiberica, S.A. | Composiciones para la piel |
CN107183457A (zh) * | 2017-06-27 | 2017-09-22 | 厦门友和邦生物科技有限公司 | 一种益生菌果汁饮料及其制备方法 |
CN109988686A (zh) * | 2019-04-10 | 2019-07-09 | 陕西杨凌长生生态农林科技有限公司 | 一种燕麦甜胚及饮料的制作方法 |
CN110140839A (zh) * | 2019-06-28 | 2019-08-20 | 益倍(武汉)健康科技有限公司 | 一种含有谷胱甘肽的美白饮制备的方法 |
CN112868953B (zh) * | 2021-02-26 | 2023-07-21 | 玉林师范学院 | 一种激光辐照联合磁场酶解制备百香果果汁的方法 |
KR102456854B1 (ko) * | 2021-05-26 | 2022-10-24 | 이용화 | 기능성 식품 제조용 원료 조성물 및 이를 이용한 기능성 식품 제조 방법 |
CN113295802A (zh) * | 2021-07-12 | 2021-08-24 | 千世泰生物科技(青岛)有限公司 | 一种含透明质酸钠的液体饮料及其中透明质酸钠含量检测方法 |
CN117076958A (zh) * | 2023-10-17 | 2023-11-17 | 湖南半岛医疗科技有限公司 | 治疗参数推荐系统 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05146279A (ja) * | 1991-11-26 | 1993-06-15 | Kyowa Hakko Kogyo Co Ltd | グルタチオン含有飲料 |
JPH07177896A (ja) * | 1993-12-22 | 1995-07-18 | Kohjin Co Ltd | アスコルビン酸を酸化する酵素を用いた酸化型グルタチオ ンの製法。 |
JPH09224607A (ja) * | 1996-02-21 | 1997-09-02 | Soken:Kk | ダイエット補助食品 |
JP2003325149A (ja) * | 2002-05-10 | 2003-11-18 | Fordays Kk | 水溶性核蛋白入り健康ドリンク |
WO2006070453A1 (ja) * | 2004-12-28 | 2006-07-06 | Fordays Co., Ltd. | 健康ドリンク |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1023409C (zh) * | 1989-07-11 | 1994-01-05 | 杨振华 | 一种营养液的生产方法 |
JP3053900B2 (ja) | 1991-02-27 | 2000-06-19 | オリエンタル酵母工業株式会社 | グルタチオンの安定化法及びそれを含有する飲料 |
JPH08275752A (ja) | 1995-04-07 | 1996-10-22 | Riken Vitamin Co Ltd | ストレス改善食品 |
DE69841217D1 (de) * | 1997-01-13 | 2009-11-19 | Univ Emory | Glutathion zur behandlung von influenzainfektionen |
CN1381558A (zh) * | 2002-04-26 | 2002-11-27 | 徐铁龙 | 营养保健饮品 |
US6946551B2 (en) * | 2003-03-12 | 2005-09-20 | New Life Resources, Llc | Preparation of hyaluronic acid from eggshell membrane |
JP2005204504A (ja) | 2004-01-20 | 2005-08-04 | Fiburo Seiyaku Kk | 田七人参、鬱金および蛇胆を原料とした若返り効果を有する顆粒状食品の製造方法 |
TWM269318U (en) * | 2004-12-28 | 2005-07-01 | Winnie Steel Co Ltd | Connection/snap-on structure for flat steel plate |
KR100688867B1 (ko) * | 2005-03-30 | 2007-03-02 | 포-데이즈 가부시키가이샤 | 건강 드링크 |
JP2008056628A (ja) | 2006-09-01 | 2008-03-13 | Fancl Corp | 睡眠誘導剤、ストレス性不眠症改善剤 |
JP2006348052A (ja) | 2006-09-22 | 2006-12-28 | Fancl Corp | グルタチオン増強用組成物 |
JP2010030901A (ja) | 2006-11-17 | 2010-02-12 | Kaneka Corp | ストレス症状の緩和または予防剤 |
CN101278736B (zh) * | 2008-03-28 | 2014-05-07 | 西安力邦制药有限公司 | 一种适合亚洲人群营养支持的均衡肠内全营养制剂 |
JP5561845B2 (ja) | 2008-09-25 | 2014-07-30 | 株式会社リンフォテック | 内因性dhea−sを増加させるための製剤およびその製造方法、ならびに内因性dhea−sを増加させるための方法 |
CN102038262A (zh) * | 2010-12-30 | 2011-05-04 | 东莞市德亨饮料食品有限公司 | 一种具有美容功能的玉米汁饮料及其制备方法 |
-
2012
- 2012-10-11 US US14/350,519 patent/US20140302171A1/en not_active Abandoned
- 2012-10-11 CN CN201810391200.2A patent/CN108354102A/zh not_active Withdrawn
- 2012-10-11 JP JP2013538440A patent/JP6138048B2/ja active Active
- 2012-10-11 CN CN201280049522.XA patent/CN103874431A/zh active Pending
- 2012-10-11 KR KR1020147007511A patent/KR101656224B1/ko active IP Right Grant
- 2012-10-11 WO PCT/JP2012/006525 patent/WO2013054525A1/ja active Application Filing
-
2018
- 2018-07-13 US US16/034,949 patent/US20180344874A1/en not_active Abandoned
- 2018-10-29 HK HK18113768.3A patent/HK1254518A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05146279A (ja) * | 1991-11-26 | 1993-06-15 | Kyowa Hakko Kogyo Co Ltd | グルタチオン含有飲料 |
JPH07177896A (ja) * | 1993-12-22 | 1995-07-18 | Kohjin Co Ltd | アスコルビン酸を酸化する酵素を用いた酸化型グルタチオ ンの製法。 |
JPH09224607A (ja) * | 1996-02-21 | 1997-09-02 | Soken:Kk | ダイエット補助食品 |
JP2003325149A (ja) * | 2002-05-10 | 2003-11-18 | Fordays Kk | 水溶性核蛋白入り健康ドリンク |
WO2006070453A1 (ja) * | 2004-12-28 | 2006-07-06 | Fordays Co., Ltd. | 健康ドリンク |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017009427A (ja) * | 2015-06-22 | 2017-01-12 | 株式会社ファンケル | 頭皮の圧縮応力の評価方法 |
JP2019001766A (ja) * | 2017-06-20 | 2019-01-10 | 国立大学法人北海道大学 | 脂質吸収抑制用剤 |
JP2019131517A (ja) * | 2018-02-01 | 2019-08-08 | エスエス製薬株式会社 | 内服液 |
JP7057150B2 (ja) | 2018-02-01 | 2022-04-19 | エスエス製薬株式会社 | 内服液 |
WO2020027012A1 (ja) * | 2018-07-30 | 2020-02-06 | 味の素株式会社 | 大豆蛋白質飲料 |
WO2021182534A1 (ja) * | 2020-03-12 | 2021-09-16 | フォーデイズ株式会社 | 水溶性核タンパクを含有する健康飲料 |
JP7180935B1 (ja) | 2021-09-14 | 2022-11-30 | プラス・レイ株式会社 | 液状飲料組成物 |
JP2023042506A (ja) * | 2021-09-14 | 2023-03-27 | プラス・レイ株式会社 | 液状飲料組成物 |
WO2023157802A1 (ja) * | 2021-09-14 | 2023-08-24 | プラス・レイ株式会社 | 液状飲料組成物及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2013054525A1 (ja) | 2015-03-30 |
HK1254518A1 (zh) | 2019-07-19 |
CN103874431A (zh) | 2014-06-18 |
US20180344874A1 (en) | 2018-12-06 |
KR20140051446A (ko) | 2014-04-30 |
JP6138048B2 (ja) | 2017-06-07 |
KR101656224B1 (ko) | 2016-09-09 |
CN108354102A (zh) | 2018-08-03 |
US20140302171A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6138048B2 (ja) | システインペプチド含有健康飲料 | |
Malaguarnera et al. | L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial | |
Moynihan et al. | Do implant-supported dentures facilitate efficacy of eating more healthily? | |
Ritz | Factors affecting energy and macronutrient requirements in elderly people | |
JP2005513107A (ja) | (−)−ヒドロキシクエン酸、クロム、およびギムネマ酸を含有する組成物、および健常体重を促進する方法と関連する健康因子を改善する方法 | |
CN100477930C (zh) | 健康饮料 | |
Gonzalez et al. | Calcium intake and 10-year weight change in middle-aged adults | |
Holford | Depression: the nutrition connection | |
WO2019046735A1 (en) | HEALTH PROMOTING COMPOSITION AND METHODS OF USING COMPLEMENT-RELATED APPLICATIONS | |
JP3899436B2 (ja) | 水溶性核蛋白入り健康ドリンク | |
RU2657824C1 (ru) | Способ биокоррекции преждевременного старения организма и кожи | |
EP2989903A1 (en) | Food supplement for people with down syndrome, autism spectrum disorder and/or attention deficit disorder with or without hyperactivity | |
CN101156857A (zh) | 一种复合维生素及其制备方法和应用 | |
JP6096964B2 (ja) | セラミド合成促進用飲食品 | |
KR102077374B1 (ko) | 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물 | |
JP2004083416A (ja) | 皮膚外用剤並びに飲食品 | |
Jung et al. | Weight reduction effects of yeast hydrolysate below 10 kDa on obese young women | |
RU2680389C1 (ru) | Способ коррекции нарушений метаболических процессов в соединительной ткани | |
CN107115332A (zh) | 一种用于治疗运动神经元病的组合物及其用途 | |
KR100688867B1 (ko) | 건강 드링크 | |
RU2377009C1 (ru) | Биологически активная добавка, способствующая снижению массы тела | |
WO2023191016A1 (ja) | フィブリリン産生促進剤、化粧料組成物又は皮膚外用剤、経口投与剤、及びエラスチン線維産生促進剤 | |
WO2021182534A1 (ja) | 水溶性核タンパクを含有する健康飲料 | |
Yonei et al. | Anti-glycation and improvement microbiota by Geranium dielsianum extract: Relation to health problems in athletes. | |
US20100151066A1 (en) | Composition for suppressing appetite, improving tone and mood, with a natural antidepressant activity and with an antiasthenic effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12840181 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2013538440 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147007511 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14350519 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12840181 Country of ref document: EP Kind code of ref document: A1 |